You are here


Definition of Advanced Cell Therapy Trials:

We define Advanced Cell Therapy as all therapies in which cells are more than minimally manipulated, and/or their action is not homologous.

Our definition is similar to the European Medicines Agency (EMA) definition of Advanced Therapy Medicinal Product (ATMP): “Medicinal product for human use that is a gene therapy medicinal product, a somatic cell therapy medicinal product or tissue engineered product” (EMA ATMP Reg. No. 1394/2007)

The definition of Advanced Cell Therapy overlaps with, but is not the same as, Regenerative Medicine, which is defined as therapy that "replaces or regenerates human cells, tissue or organs, to restore or establish normal function" (Mason & Dunnil 2008)

Advanced Cell Therapy encompasses Regenerative Medicine with cells, and in addition includes Cellular Immunotherapy, Gene Therapy that is delivered by cells, and Tissue Engineering that is seeded or administered with cells.

Note that Advanced Cell Therapy does not include Hematopoietic Stem Cell Transplants (HSCT), unless the cells are more than minimally manipulated before they are administered. Advanced Cell Therapy does not include Gene Therapy or Tissue Engineering that does not employ cells.

Please bear in mind that the other compilations in our comparison table each have their own selection criteria for compiling trials.


Acronym Definition
AE Adverse Events
ALDHbr cells Aldehyde Dehydrogenase Bright Cells
ALL Acute Lymphoblastic Leukemia
Allo Allogeneic
AML Acute Myeloid Leukemia
APH Apheresis (leukapheresis)
AT Adipose Tissue
Auto Autologous
BM Bone Marrow
BMAC Bone Marrow Aspirate Concentrate
CAR Chimeric Antigen Receptors
CB Cord Blood
CIK Cytokine-induced Killer Cells
CLL Chronic Lymphocytic Leukemia
CMV Cytomegalovirus
CR Complete Remission
CRS Cytokine Release Syndrome
CTL Cytotoxic T Lymphocytes
Cy Cyclophosphamide
DC Dendritic Cells
DLBCL Diffuse Large B Cell Lymphoma
DLCL Diffuse Large Cell Lymphoma
DLI Donor Lymphocyte Infusion
DP Dental Pulp
EPC Endothelial Progenitor Cells
ESC Embryonic Stem Cells
FCRx Facilitating Cell Platform Technology (Hematopoietic Cells Bioengineered)
Flu Fludarabine
hRPE-ESC Human Retinal Pigmented Epithelial- Embryonic Stem Cells
HSC Hematopoietic Stem Cells
HSCT Hematopoietic Stem Cell Transplant
HSPC Hematopoietic Stem Progenitor Cells
HuCNS-SC Human Central Nervous System-Stem Cells
IV intravenous
lenti- lentiviral vector
MAPC Multipotent Adult Progenitor Cells
MIL Marrow Infiltrating Lymphocytes
MNC Mononuclear Cells
MRD Minimal Residual Disease
MSC Mesenchymal Stem/Stromal Cells
NHL Non-Hodgkins Lymphoma
NK Natural Killer cells
NKT Natural Killer T-Cell
ORR Overall/Objective Response Rate
OS Overall Survival
PB Peripheral Blood
PD Progressive Disease
PR Partial Response
pedi- Pediatric Patients
PFS Progression-Free Survival
PLL ProLymphocytic Leukemia
PTS Patients
retro- retroviral vector
Ritu Rituximab
RPE-iPS Retinal Pigmented Epithelial-induced Pluripotent Stem Cells
SD Stable Disease
SLL Small Lymphocytic Lymphoma
SVF Stromal Vascular Fraction
TCR T-Cell Receptor
TIL Tumor-infiltrating lymphocytes
UC Umbilical Cord
VST Virus-Specific T-Cell